Ketamine in treatment-resistant depression: A review of completed investigations
S. Verma
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Sample size | 360 |
| Population | Patients with treatment-resistant depression across 15 clinical trials |
| Intervention | Ketamine |
| Measures | Montgomery-Åsberg Depression Rating Scale, Hamilton Rating Scale for Depression |
| Topics | Depression Esketamine Ketamine |
| Key findings | Across 15 trials of 360 patients with treatment-resistant depression, 15-90% of patients showed a greater than 50% reduction in depression rating scale scores at 4 hours after infusional ketamine, but response rates decreased significantly over time, indicating a rapid yet short-lived antidepressant effect. |
Abstract
Background and
Objective: The objective was to evaluate clinical trial data on the use of ketamine in treating treatment-resistant depression (TRD).
Materials and Methods: PubMed search (November 2012) was initiated using the keywords: Ketamine, resistant depression. Inclusion criterion included: English language publications describing clinical trial reports on humans with TRD.
Results: A total of 360 patients across 15 clinical trials with TRD were treated with infusional ketamine. On average 15-90% of patients reported a >50% decrease in their baseline Montgomery-Åsberg Depression Rating Scale/Hamilton Rating Scale for Depression scores at 4 h. Response rates decreased significantly as time progressed.
Conclusion: Infusional ketamine has a significant rapid, short-term antidepressant effect in the treatment of TRD.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |
Citations in the library
Cites 12
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial The International Journal of Neuropsychopharmacology March 17, 2009
- An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression The International Journal of Neuropsychopharmacology November 1, 2011
- Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. European Archives of Psychiatry and Clinical Neuroscience December 2011
- Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry June 1, 2011
and 7 more in the library